These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26868507)

  • 41. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients.
    Sager PT; Capece R; Lipka L; Strony J; Yang B; Suresh R; Mitchel Y; Veltri E
    Atherosclerosis; 2005 Apr; 179(2):361-7. PubMed ID: 15777554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy.
    Zinellu A; Sotgia S; Loriga G; Deiana L; Satta AE; Carru C
    Amino Acids; 2012 Oct; 43(4):1499-507. PubMed ID: 22278741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels.
    Liberopoulos EN; Makariou SE; Moutzouri E; Kostapanos MS; Challa A; Elisaf M
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):229-33. PubMed ID: 23288870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease.
    Sbarouni E; Kroupis C; Kyriakides ZS; Koniavitou K; Kremastinos DT
    Eur Heart J; 2000 Jun; 21(12):975-80. PubMed ID: 10901509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
    Catapano A; Brady WE; King TR; Palmisano J
    Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
    Gaudiani LM; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
    Diabetes Obes Metab; 2005 Jan; 7(1):88-97. PubMed ID: 15642080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia.
    Serrano CV; Yoshida VM; Venturinelli ML; D'Amico E; Monteiro HP; Ramires JA; da Luz PL
    Atherosclerosis; 2001 Aug; 157(2):505-12. PubMed ID: 11472753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments.
    Desideri G; Croce G; Tucci M; Passacquale G; Broccoletti S; Valeri L; Santucci A; Ferri C
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5341-7. PubMed ID: 14602771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels.
    Lewandowski J; Siński M; Puchalska L; Symonides B; Gaciong Z
    J Am Soc Hypertens; 2014 Oct; 8(10):715-23. PubMed ID: 25418493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance.
    Victor VM; Rocha M; Bañuls C; Alvarez A; de Pablo C; Sanchez-Serrano M; Gomez M; Hernandez-Mijares A
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3115-22. PubMed ID: 21778215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
    Guimarães ES; Cerda A; Dorea EL; Bernik MMS; Gusukuma MC; Pinto GA; Fajardo CM; Hirata MH; Hirata RDC
    Cardiovasc Ther; 2017 Dec; 35(6):. PubMed ID: 28940978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis.
    Barbosa CP; Bracht L; Ames FQ; de Souza Silva-Comar FM; Tronco RP; Bersani-Amado CA
    Inflammation; 2017 Apr; 40(2):717-724. PubMed ID: 28028755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Native LDL-cholesterol mediated monocyte adhesion molecule overexpression is blocked by simvastatin.
    Serrano CV; Pesaro AE; de Lemos JA; Rached F; Segre CA; Gomes F; Ribeiro AF; Nicolau JC; Yoshida VM; Monteiro HP
    Cardiovasc Drugs Ther; 2009 Jun; 23(3):215-20. PubMed ID: 19125317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients.
    Rovira-Llopis S; Bañuls C; de Marañon AM; Diaz-Morales N; Jover A; Garzon S; Rocha M; Victor VM; Hernandez-Mijares A
    Free Radic Biol Med; 2017 Jul; 108():155-162. PubMed ID: 28359952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.